Issue link: https://www.e-digitaleditions.com/i/1417310
30 OctOber 2021 Inhalation Employing new in vitro testing Proveris ® Laboratories offers orally inhaled and nasal drug product development (OINDP) exper- tise to pharmaceutical developers, including contract services employing the new, innovative in vitro techniques outlined by the US FDA. ese include measuring spray velocity and evaporation rate, and quantifying deposition of inhaled drug products using human-realistic models. e performance of OINDPs is affected by a combination of formula- tion, device and patient usage. Employing alternative in vitro approaches that are human-realistic can enable companies to make data-driven decisions and expedite product development and approval while saving time and resources. Proveris Scientific Corporation US: +1 508 460-8822 www.proveris.com Inhalation formulation services Lonza Small Molecules provides integrated dry powder inhaler (DPI) development services to advance molecules, drawing on 25 years of experi- ence in particle engineering, formulation design and encapsulation techniques. Our premier particle engi- neering technology services, utilizing both jet milling and spray drying, are tailored to your molecule, target product profile and delivery device. Dedicated DPI formulation, analytical and manufacturing teams ensure that development timelines are met while minimizing program risk and complexity. Lonza Small Molecules US: +1 541 382-4100 www.pharma.lonza.com Bespoke inhaled formulation development i2c Pharmaceutical Services is a leading independent service provider to global pharma, medical technol- ogy and emerging companies for the development of inhaled formulations and efficient devices. i2c provides bespoke integrated services from ab initio development through clinical trials. i2c also offers Respitab ® ; this propellant-dispersible tablet is a cost-effective and innovative manufacturing platform that can facilitate transition to the next generation of pressurized metered dose inhalers (pMDIs). i2c Pharmaceutical Services UK: +44 2920 757865 www.i2cpharm.co.uk End-to-end service Recipharm offers end-to-end service from early development to commercial manufacturing for MDIs, DPIs and nasal sprays. Delivering market leading design, development and manufacturing of drug delivery devices to the global market in con- junction with Bespak by Recipharm, the integrated CDMO can comprehensively cater to inhaler and nasal projects, and provide access to a team of experts with decades of expertise that allows them to manage complexity and accelerate routes to market. ese expertise form part of Recipharm's Inhalation Solu- tions™, an end-to-end solution spanning early phase development to commercial manufacture. Recipharm Sweden: +46 8 602 52 00 www.recipharm.com